New therapies for diabetes: Incretin mimetics and gliptins

Diabetes and Primary Care

Volumn 9, Issue 2, 2007, Pages

  Munro, Nell ^a,c   Levy, Jonathan ^b   El Gayar, Heba ^c   Feher, Michael ^c  

^a Claygate   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

DPP IV inhibitors; Gliprins; GLP 1; Incretin mimetics

Indexed keywords

EID: 38349173183     PISSN: 14668955     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Agerso H, Jensen LB, Elbrond B eL al (2002) The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 45:195-202
2. Ahren B (2007) DPP-4 Inhibitors - Clinical Data and Clinical Implications. Diabetes Care [Epub ahead of print]
3. Aschner P, Kipnes MS, Lunceford JK et al (2006) Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29: 2632-7
4. Azuma K, Radikova Z, Mancino JM et al (2006) DPP-4 inhibition improves insulin resistance (IR) in type 2 diabetes mellitus. Program and abstracts of the American Diabetes Association 66th Scientific Sessions, 9-13 June 2006, Washington, DC. Abstract 5-LB
5. Buse JB, Henry RR, Han J et al (2004) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulphonylurea treated patients with type 2 diabetes. Diabetes Care 27: 2628-35
6. D'Alessio DA, Watson CE, He Y-L et al (2006) Restoration of an acute insulin response to glucose (AIRg) in drug-naïve patients with type 2 diabetes by 3-month treatment with vildagliptin. Program and abstracts of the American Diabetes Association 66th Scientific Sessions, 9-13 June 2006, Washington, DC. Abstract 454-P
7. Deacon CF (2004) Therapeutic strategies based on glucagon-like peptide 1. Diabetes 3: 2181-9
8. DeFronzo RA, Ratner RE, Han J (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in metformin-treated patients. Diabetes Care 28:1092-100
9. 1c during one-year treatment with vildagliptin in patients with type 2 diabetes. Program and abstracts of the American Diabetes Association 66th Scientific Sessions, 9-13 June 2006, Washington, DC. Abstract 120-OR
10. Drucker DJ (2001) Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. Current Pharmaceutical Design 7:1399-412
11. Drucker DJ (2003) Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Molecular Endocrinology 17:161-71
12. Elrick H, Stimmler L, Hlad CJ Jr et al (1964) Plasma insulin response to oral and intravenous glucose administration. Journal of Clinical Endocrinology and Metabolism 24:1076-82
13. Eng J, Andrews PC, Kleinman WA et al (1990) Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom. Journal of Biological Chemistry 265:20259-62
14. Eng J, Kleiman WA, Singh L et al (1992) Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. Journal of Biological Chemistry 267: 7402-5
15. Fineman MS, Shen LZ, Taylor K et al (2004) Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes/Metabolism Research and Reviews 20:411-17
16. Fonseca V, Dejager S, Albrecht D, Shirt L, Schweizer A (2006) Vildagliptin as an add-on to insulin in patients with type 2 diabetes. Program and abstracts of the American Diabetes Association 66th Scientific Sessions, 9-13 June 2006, Washington, DC. Abstract 467-P
17. Green BD, Flatt PR, Bailey CJ (2006) Dipeptidyl peptidase (DPP-IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diabetes and Vascular Disease Research 3: 159-65
18. Heine RJ, Van Gaal LF, Johns D et al (2005) Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Annals of Internal Medicine 143: 559-69
19. Idris I, Donnelly R (2007) Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diabetes, Obesity and Metabolism 9: 153-65
20. Juhl CB, Hollingdal M, Sturis J et al (2002) Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 51: 424-9
21. Kendall DM, Riddle MC, Rosenstock J et al (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients treated with metformin and a sulfonylurea. Diabetes Care 28: 1083-91
22. Levy JC (2006) Therapeutic intervention in the GLP-1 pathway in type 2 diabetes. Diabetic Medicine 23(Suppl 1): 14-19
23. Madsbad S, Schmitz O, Ranstam J (2004) Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 27: 1335-42
24. McIntyre N, Holdsworth CD, Turner DS (1964) New interpretation of oral glucose tolerance. Lancet 41: 20-1
25. Nauck M, Stockmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29: 46-52
26. Nauck MA, Hompesch M, Filipczak R et al (2006) Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Experimental and Clinical Endocrinology and Diabetes 114: 417-23
27. Nonaka K, Kakikawa T, Sato A et al (2006) Twelve-week efficacy and tolerability of sitagliptin, a dipeptidyl peptidase-IV (DPP-4) inhibitor in Japanese patients with T2DM. Program and abstracts of the American Diabetes Association 66th Scientific Sessions; 9-13 June, Washington, DC. Abstract 537-P
28. Perley MJ, Kipnis DM (1967) Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. Journal of Clinical Investigation 46: 1954-62
29. Raz I, Hanefeld M, Xu L et at (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49: 2564-71
30. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators (2003) The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26: 3080-6
31. Riddle MC, Henry RR, Poon TH et al (2006) Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metabolism Research and Reviews 22: 483-91
32. Rosenstock J, Brazg R, Andryuk PJ et al (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clinical Therapeutics 28: 1556-68
33. Rosenstock J, Baron MA, Dejager S et al (2007) Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 30: 217-23
34. Ruddy MK, Bergman AJ, Zheng W et al (2006) Sitagliptin, a DPP-4 inhibitor, does not inhibit the pharmacokinetics of the sulfonylurea glyburide. Program and abstracts of the American Diabetes Association 66th Scientific Sessions, 9-13 June 2006, Washington, DC. Abstract 558-P
35. Rudovich A, Kaiser S, Engeli S, Pfeiffer AFH (2005) Gastric inhibitory polypeptide receptors are present in human subcutaneous adipose tissue: effects of central obesity and weight loss. Program and abstracts of the European Association for the Study of Diabetes 41st Annual Meeting; 12-15 September 2005; Athens, Greece. Abstract 549
36. Triplitt C, Wright A, Chiquette E (2006) Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus. Pharmacotherapy 26: 360-74
37. Vilsboll T, Holst JJ (2004) Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 47: 357-66
38. Zander M, Madsbad S, Madsen JL, Holst JJ (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and ß-cell function in type 2 diabetes: a parallel-group study. Lancet 359: 824-30